Literature DB >> 9469439

Effects of aminoguanidine on latent murine tuberculosis.

J L Flynn1, C A Scanga, K E Tanaka, J Chan.   

Abstract

A unique feature of Mycobacterium tuberculosis is its ability to establish latent infection in the human host, which can reactivate to cause disease years later. In the present study, the mechanisms involved in the control of latent tuberculous infection were examined using two murine experimental tuberculosis models. Analysis of the model involving infection of mice with a relatively low inoculum of the virulent Erdman strain of M. tuberculosis indicated that in vivo inhibition of reactive nitrogen intermediate (RNI) production by the nitric oxide synthase inhibitor aminoguanidine resulted in reactivation. This reactivation was evidenced by hepatosplenomegaly, a robust tissue granulomatous reaction, and increased bacillary load. IFN-gamma, TNF-alpha, and inducible nitric oxide synthase were all expressed throughout the latent phase of infection. Reactivation of latent tuberculous infection by aminoguanidine treatment was confirmed using a second murine tuberculosis model based on treatment with antimycobacterial drugs. Results obtained using this drug-based model also suggested the existence of an RNI-independent antimycobacterial mechanism(s) operative in the latent phase of infection. Together, these data suggest that both RNI-dependent and -independent mechanisms contribute to the prevention of tuberculous reactivation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9469439

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  84 in total

Review 1.  Tuberculosis: latency and reactivation.

Authors:  J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 2.  Immunoregulatory and antimicrobial effects of nitrogen oxides.

Authors:  Joan B Mannick
Journal:  Proc Am Thorac Soc       Date:  2006-04

3.  Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis.

Authors:  JoAnn M Tufariello; Kaixia Mi; Jiayong Xu; Yukari C Manabe; Anup K Kesavan; Joshua Drumm; Kathryn Tanaka; William R Jacobs; John Chan
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Individual Mycobacterium tuberculosis resuscitation-promoting factor homologues are dispensable for growth in vitro and in vivo.

Authors:  JoAnn M Tufariello; William R Jacobs; John Chan
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  The role of nitric oxide in lung innate immunity: modulation by surfactant protein-A.

Authors:  Philip O'Reilly; Judy M Hickman-Davis; Philip McArdle; K Randall Young; Sadis Matalon
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

Review 7.  Disruption of immune regulation by microbial pathogens and resulting chronic inflammation.

Authors:  Kenneth Barth; Daniel G Remick; Caroline A Genco
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

8.  Guinea pig model of Mycobacterium tuberculosis latent/dormant infection.

Authors:  Suely S Kashino; Danielle R Napolitano; Ziedonis Skobe; Antonio Campos-Neto
Journal:  Microbes Infect       Date:  2008-09-06       Impact factor: 2.700

9.  Reactive nitrogen intermediates have a bacteriostatic effect on Mycobacterium tuberculosis in vitro.

Authors:  Marcia A Firmani; Lee W Riley
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Early induction of humoral and cellular immune responses during experimental Mycobacterium avium subsp. paratuberculosis infection of calves.

Authors:  W R Waters; J M Miller; M V Palmer; J R Stabel; D E Jones; K A Koistinen; E M Steadham; M J Hamilton; W C Davis; J P Bannantine
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.